Cargando…
Human papillomavirus infection and lung adenocarcinoma: special benefit is observed in patients treated with immune checkpoint inhibitors
BACKGROUND: Human papilloma virus (HPV) has been associated with the development and modulation of response in a series of neoplasms. In the case of lung adenocarcinoma, its role in etiology and pathogenesis is still controversial. Considering that this infection brings foreign epitopes, it could be...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434139/ https://www.ncbi.nlm.nih.gov/pubmed/35753086 http://dx.doi.org/10.1016/j.esmoop.2022.100500 |
_version_ | 1784780803900702720 |
---|---|
author | Rojas, L. Mayorga, D. Ruiz-Patiño, A. Rodríguez, J. Cardona, A.F. Archila, P. Avila, J. Bravo, M. Ricaurte, L. Sotelo, C. Arrieta, O. Zatarain-Barrón, Z.L. Carranza, H. Otero, J. Vargas, C. Barrón, F. Corrales, L. Martín, C. Recondo, G. Pino, L.E. Bermudez, M.A. Gamez, T. Ordoñez-Reyes, C. García-Robledo, J.E. de Lima, V.C. Freitas, H. Santoyo, N. Malapelle, U. Russo, A. Rolfo, C. Rosell, R. |
author_facet | Rojas, L. Mayorga, D. Ruiz-Patiño, A. Rodríguez, J. Cardona, A.F. Archila, P. Avila, J. Bravo, M. Ricaurte, L. Sotelo, C. Arrieta, O. Zatarain-Barrón, Z.L. Carranza, H. Otero, J. Vargas, C. Barrón, F. Corrales, L. Martín, C. Recondo, G. Pino, L.E. Bermudez, M.A. Gamez, T. Ordoñez-Reyes, C. García-Robledo, J.E. de Lima, V.C. Freitas, H. Santoyo, N. Malapelle, U. Russo, A. Rolfo, C. Rosell, R. |
author_sort | Rojas, L. |
collection | PubMed |
description | BACKGROUND: Human papilloma virus (HPV) has been associated with the development and modulation of response in a series of neoplasms. In the case of lung adenocarcinoma, its role in etiology and pathogenesis is still controversial. Considering that this infection brings foreign epitopes, it could be of prognostic significance in patients with lung adenocarcinoma treated with immunotherapy. METHODS: In a retrospective cohort study we evaluated the presence of HPV genomic material in lung adenocarcinoma primary lesions with the INNO-LiPA platform. Viral replication was also evaluated by detecting the presence of oncoprotein E6/E7 messenger RNA (mRNA) by quantitative RT-PCR. To confirm possible hypotheses regarding viral oncogenesis, vascular endothelial growth factor (VEGF) and hypoxia-inducible factor 1 (HIF1) were evaluated with stromal fibrosis and immunoscore. RESULTS: A total of 133 patients were included in the analysis, of whom 34 tested positive for HPV, reaching an estimated prevalence of 25.6% [95% confidence interval (CI) 18.2% to 32.9%]. E6/7 mRNA was identified in 28 out of the 34 previously positive cases (82.3%). In immune checkpoint inhibitor (ICI)-treated patients, the median overall survival reached 22.3 months [95% CI 19.4 months- not reached (NR)] for HPV-negative and was not reached in HPV-positive (HPV+) ones (95% CI 27.7-NR; P = 0.008). With regard to progression-free survival, HPV− patients reached a median of 9.2 months (95% CI 7.9-11.2 months) compared to 14.3 months (95% CI 13.8-16.4 months) when HPV was positive (P = 0.001). The overall response rate for HPV+ patients yielded 82.4% compared to 47.1% in negative ones. No differences regarding programmed death-ligand 1, VEGF, HIF1, stromal fibrosis, or immunoscore were identified. CONCLUSIONS: In patients with HPV+ lung adenocarcinoma, a significant benefit in overall response and survival outcomes is observed. |
format | Online Article Text |
id | pubmed-9434139 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-94341392022-09-02 Human papillomavirus infection and lung adenocarcinoma: special benefit is observed in patients treated with immune checkpoint inhibitors Rojas, L. Mayorga, D. Ruiz-Patiño, A. Rodríguez, J. Cardona, A.F. Archila, P. Avila, J. Bravo, M. Ricaurte, L. Sotelo, C. Arrieta, O. Zatarain-Barrón, Z.L. Carranza, H. Otero, J. Vargas, C. Barrón, F. Corrales, L. Martín, C. Recondo, G. Pino, L.E. Bermudez, M.A. Gamez, T. Ordoñez-Reyes, C. García-Robledo, J.E. de Lima, V.C. Freitas, H. Santoyo, N. Malapelle, U. Russo, A. Rolfo, C. Rosell, R. ESMO Open Original Research BACKGROUND: Human papilloma virus (HPV) has been associated with the development and modulation of response in a series of neoplasms. In the case of lung adenocarcinoma, its role in etiology and pathogenesis is still controversial. Considering that this infection brings foreign epitopes, it could be of prognostic significance in patients with lung adenocarcinoma treated with immunotherapy. METHODS: In a retrospective cohort study we evaluated the presence of HPV genomic material in lung adenocarcinoma primary lesions with the INNO-LiPA platform. Viral replication was also evaluated by detecting the presence of oncoprotein E6/E7 messenger RNA (mRNA) by quantitative RT-PCR. To confirm possible hypotheses regarding viral oncogenesis, vascular endothelial growth factor (VEGF) and hypoxia-inducible factor 1 (HIF1) were evaluated with stromal fibrosis and immunoscore. RESULTS: A total of 133 patients were included in the analysis, of whom 34 tested positive for HPV, reaching an estimated prevalence of 25.6% [95% confidence interval (CI) 18.2% to 32.9%]. E6/7 mRNA was identified in 28 out of the 34 previously positive cases (82.3%). In immune checkpoint inhibitor (ICI)-treated patients, the median overall survival reached 22.3 months [95% CI 19.4 months- not reached (NR)] for HPV-negative and was not reached in HPV-positive (HPV+) ones (95% CI 27.7-NR; P = 0.008). With regard to progression-free survival, HPV− patients reached a median of 9.2 months (95% CI 7.9-11.2 months) compared to 14.3 months (95% CI 13.8-16.4 months) when HPV was positive (P = 0.001). The overall response rate for HPV+ patients yielded 82.4% compared to 47.1% in negative ones. No differences regarding programmed death-ligand 1, VEGF, HIF1, stromal fibrosis, or immunoscore were identified. CONCLUSIONS: In patients with HPV+ lung adenocarcinoma, a significant benefit in overall response and survival outcomes is observed. Elsevier 2022-06-23 /pmc/articles/PMC9434139/ /pubmed/35753086 http://dx.doi.org/10.1016/j.esmoop.2022.100500 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Research Rojas, L. Mayorga, D. Ruiz-Patiño, A. Rodríguez, J. Cardona, A.F. Archila, P. Avila, J. Bravo, M. Ricaurte, L. Sotelo, C. Arrieta, O. Zatarain-Barrón, Z.L. Carranza, H. Otero, J. Vargas, C. Barrón, F. Corrales, L. Martín, C. Recondo, G. Pino, L.E. Bermudez, M.A. Gamez, T. Ordoñez-Reyes, C. García-Robledo, J.E. de Lima, V.C. Freitas, H. Santoyo, N. Malapelle, U. Russo, A. Rolfo, C. Rosell, R. Human papillomavirus infection and lung adenocarcinoma: special benefit is observed in patients treated with immune checkpoint inhibitors |
title | Human papillomavirus infection and lung adenocarcinoma: special benefit is observed in patients treated with immune checkpoint inhibitors |
title_full | Human papillomavirus infection and lung adenocarcinoma: special benefit is observed in patients treated with immune checkpoint inhibitors |
title_fullStr | Human papillomavirus infection and lung adenocarcinoma: special benefit is observed in patients treated with immune checkpoint inhibitors |
title_full_unstemmed | Human papillomavirus infection and lung adenocarcinoma: special benefit is observed in patients treated with immune checkpoint inhibitors |
title_short | Human papillomavirus infection and lung adenocarcinoma: special benefit is observed in patients treated with immune checkpoint inhibitors |
title_sort | human papillomavirus infection and lung adenocarcinoma: special benefit is observed in patients treated with immune checkpoint inhibitors |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434139/ https://www.ncbi.nlm.nih.gov/pubmed/35753086 http://dx.doi.org/10.1016/j.esmoop.2022.100500 |
work_keys_str_mv | AT rojasl humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors AT mayorgad humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors AT ruizpatinoa humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors AT rodriguezj humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors AT cardonaaf humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors AT archilap humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors AT avilaj humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors AT bravom humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors AT ricaurtel humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors AT soteloc humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors AT arrietao humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors AT zatarainbarronzl humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors AT carranzah humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors AT oteroj humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors AT vargasc humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors AT barronf humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors AT corralesl humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors AT martinc humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors AT recondog humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors AT pinole humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors AT bermudezma humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors AT gamezt humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors AT ordonezreyesc humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors AT garciarobledoje humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors AT delimavc humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors AT freitash humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors AT santoyon humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors AT malapelleu humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors AT russoa humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors AT rolfoc humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors AT rosellr humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors AT humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors |